about
Translating pharmacogenomics: challenges on the road to the clinicUsing the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levelsEmerging PSA-based tests to improve screeningKallikreins as biomarkers for prostate cancerA Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside PotentialRobust prostate cancer marker genes emerge from direct integration of inter-study microarray data.What can proteomic analyses contribute to understanding the molecular biology and clinical behavior of prostate cancer?Alterations in the serum glycome due to metastatic prostate cancerMethods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.Constitutive and Inducible Expression of Invasion-related Factors in PC-3 Prostate Cancer Cells.Proteomics approaches to urologic diseases.Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker.Identifying cancer biomarkers by mass spectrometry-based glycomicsSystematic, evidence-based discovery of biomarkers at the NCI.Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.Biochemical individuality reflected in chromatographic, electrophoretic and mass-spectrometric profilesProfiling of human serum glycans associated with liver cancer and cirrhosis by IMS-MSBeyond PSA: the next generation of prostate cancer biomarkers.External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.Biomarkers and mechanisms associated with recurrent prostate cancer.Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening.Biomarkers in localized prostate cancer.Development of Interpretable Predictive Models for BPH and Prostate Cancer.Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.Perineural invasion status, Gleason score and number of positive cores in biopsy pathology are predictors of positive surgical margin following laparoscopic radical prostatectomy.Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria.The Correlation between Diffusion-Weighted Imaging and Histopathological Evaluation of 356 Prostate Biopsy Sites in Patients with Prostatic Diseases.Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration.Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids.Prostate cancer
P2860
Q21092371-3F90C543-FE16-4DE0-9ACE-336C04F54B73Q24550631-FDC4961F-BC05-479D-BCD2-31BA05A7B49AQ26828563-63E3D5C6-45CE-48D5-9371-CDFCEC34DA35Q26862434-B89EB8EA-4D2E-4140-BD59-7D18FEE7DAEEQ27022638-46AC2C7A-97D7-4452-B782-404DC088672EQ31002200-0368EA84-AB2D-4D1A-8A02-CD6CC5E64E0DQ33217474-6970A65F-16BA-4C9F-92C0-87EB5DAE57F9Q33282042-74E9D8B3-1CF5-40B1-BA01-94C4190FBCF9Q33573087-976DA706-612B-48DE-963F-9E948ECE7E97Q33989110-220B4CD6-AC21-4290-8A82-54970F488EE5Q34381513-81FF0207-5F01-42EF-9EA2-AB5D5E51D069Q35820978-0816A6BD-7690-4FA0-B503-E1E72902A3FCQ36505667-1567B19F-CA97-40CC-AD2A-916B39036219Q36524546-FBB1737B-F25B-46DD-8226-652276169737Q36904006-9325625D-DF5D-4D57-89BA-9B3B84B680D8Q36922015-D83CF518-4B4D-403A-B3DE-AD38EA2679BFQ36949577-470D94F8-9398-489A-88EA-8A898E56A979Q37015350-7943F8CC-1921-45E3-9B29-5BD64083744BQ37055406-CA4210B3-C462-4CD4-B3E9-5771449E6D37Q37238101-2AE8A9AA-F81F-4F52-ABC3-459233702A72Q37244115-4AF3261D-E229-4280-8B8B-B576911801C8Q37260341-87E69BF3-83AC-4548-86ED-7F899743C5ADQ37460195-3E91FFDA-5C6D-424B-B5A6-CBBC6EE293E3Q38175727-9ABB07AE-0CF2-447C-8E5B-A9A9CEA79D06Q38668005-85D7E384-8693-4733-82F5-E3A656951F26Q38697114-9F5CA409-1189-427E-B7B2-59DC304EBD9DQ40264276-D51A3F4F-9688-4E90-AD5D-706C8982B888Q40747388-9D42F308-B328-45C4-9465-59D3FAE89A24Q40993274-A6AB6708-8A1A-49BC-8804-6EE9F943E8AFQ41495124-4B975A33-6740-4607-B643-87E27E164C6EQ42226058-3E03732B-8005-4033-B27E-C00DF4B43D97Q42256326-10B97945-E558-4185-AC85-833643FB86F0Q42487996-3700756D-63FE-4011-B790-05926C41CF33Q43200996-EBFD2415-002B-46E3-A274-D4F046F4B398Q46098777-820E1E13-B60E-48F7-A47D-6DC7BDECE52DQ53674734-C404CA3E-4276-4457-AB13-D07BE307F97EQ57656183-828F978E-6DC7-4E97-A744-FF70682A74B1
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prostate-specific antigen: current status.
@ast
Prostate-specific antigen: current status.
@en
Prostate-specific antigen: current status.
@nl
type
label
Prostate-specific antigen: current status.
@ast
Prostate-specific antigen: current status.
@en
Prostate-specific antigen: current status.
@nl
prefLabel
Prostate-specific antigen: current status.
@ast
Prostate-specific antigen: current status.
@en
Prostate-specific antigen: current status.
@nl
P1433
P1476
Prostate-specific antigen: current status.
@en
P2093
P304
P356
10.3322/CANJCLIN.49.5.264
P407
P577
1999-09-01T00:00:00Z